Navigation Links
GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
Date:11/7/2007

ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announces that its Chief Scientific Advisor Harriet Robinson, Ph.D. has been elected "Fellow of the American Association for the Advancement of Science (AAAS)." Election as a "Fellow" is an honor bestowed upon AAAS members by their peers because of their contributions to advance science or its applications. Emory University professor and Asa Griggs scholar, Dr. Robinson co-founded GeoVax Labs, Inc. and is one of the world's leading HIV/AIDS vaccine scientists.

Recognized by the AAAS section on medical sciences, Dr. Robinson was elected for her outstanding work on retrovirus biology and the development of DNA vaccines with special emphasis on HIV/AIDS vaccines. In addition to her role as GeoVax's Chief Scientific Advisor, Dr. Robinson is chair of the Division of Microbiology and Immunology at Yerkes National Primate Research Center, a professor of microbiology and immunology in Emory University School of Medicine and an investigator in the Emory Vaccine Center.

GeoVax HIV/AIDS vaccine technologies were developed by Dr. Robinson in collaboration with colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). GeoVax HIV/AIDS vaccines are moving forward in human clinical trials administered by the HIV Vaccine Trials Network (HVTN). Four (4) Phase 1 human trials involving over 115 individuals are currently underway and Phase 2 trials are being planned for 2008.

Licensed by GeoVax, this innovative, two-step vaccine administration strategy utilizes DNA vaccines to prime the human immune system and recombinant MVA vaccines to boost the immune response against the AIDS virus. Both vaccines express greater than 50% of AIDS virus' (HIV-1) components and stimulate an antibody response as well as a T-cell response. Neither vaccine can cause
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
3. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
4. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
5. New Director of Nursing Practice Named for Nurses Association
6. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
7. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
8. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
9. Keith Taft Named General Manager of UltraTape Industries
10. AIUM CEO named among most influential in radiology
11. Top Twenty Health Plan Websites Named by TheRatingsGuy.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Tarrytown, NY (PRWEB) March 26, 2015 ... conducted its 30th “Introduction to Hyperbaric Medicine” course, ... Hyperbaric Medical Society (UHMS) and the National Board ... LST provides the 40-hour course 4 times a ... facilities around the NY tri-state region; registration is ...
(Date:3/26/2015)... Innovative research and additional funding ... often fatal ruptures, says The Bee Foundation, a ... of brain aneurysms and funding innovative research that ... attention with the death of longtime WABC-TV ... Friday after suffering a ruptured brain aneurysm. (Source: ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 On March ... Wesley Matthews is out for the season with a ... occurred while the Trail Blazers were competing against Dallas, ... medicine specialist, Izzy Silva, M.D., who has treated ... injury and whether it could be prevented. , ...
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... supports the Patients’ Access to Treatments Act (PATA) ... this week by Reps. David B. McKinley (R-WV) ... will limit cost-sharing requirements for medications placed in ... accessible by reducing patients’ out-of-pocket expenses. , This ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Volunteers will ... awareness of Parkinson’s disease and funds to support the ... Ease the Burden – Find the Cure. ... will take place in more than 20 locations including, ... New Jersey, San Antonio, Minnesota, Seattle, St. Louis, New ...
Breaking Medicine News(10 mins):Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 2Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2
... , EXTON, Pa., Oct. 15 ViroPharma Incorporated,s (Nasdaq: ... to be released on Wednesday, October 28, 2009 before the ... host a conference call and live audio webcast at 9:00 ... conference call, ViroPharma management will discuss the 2009 third quarter ...
... researchers say , THURSDAY, Oct. 15 (HealthDay News) -- ... of people, potentially paving the way toward better treatments ... a crucial step forward towards developing therapies that can ... the only treatment for most advanced liver disease," the ...
... 15 Bausch & Lomb today announced the launch of ... Patient Insights at www.CenterForPatientInsights.com . The Center, ... to eye care professionals to help them better understand and ... information and serve as an easy-to-use point of entry for ...
... COAST, Fla., Oct. 15 Technology companies have been ... Incubator space has recently gathered some thoughtful discussion in ... the expansion of medical care into secondary markets. One ... , believes there,s application in off-campus medical office buildings ...
... vaccine might promote promiscuity, a national survey of girls ... did not believe the HPV vaccine protected them against ... University of Illinois at Chicago and University of Chicago ... the Journal of Adolescent Health . The ...
... technique described as a Band-Aid for damaged muscle , THURSDAY, ... toward the goal of literally rebuilding a broken heart -- ... by using a newly identified human cardiac master stem cell. ... therapy," said Dr. Kenneth Chien, director of the Massachusetts General ...
Cached Medicine News:Health News:ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009 2Health News:Liver Cells Made to Order 2Health News:Center for Patient Insights Web Site Goes Live 2Health News:Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 2Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Stem Cells Grow Heart Tissue in Lab 2Health News:Stem Cells Grow Heart Tissue in Lab 3
(Date:3/26/2015)... Md. , March 26, 2015  RegeneRx Biopharmaceuticals, ... it has received a patent acceptance notice from the ... 4 (TB4) to prevent or reduce tissue damage caused ... the case when cardiac vessels are opened after a ... when treating stroke victims. Damage can be ...
(Date:3/26/2015)... , March 26, 2015  Becton, Dickinson and ... it will commence offers to exchange all validly tendered ... CareFusion Corporation, a wholly owned subsidiary of BD, for ... the table below. A Registration Statement on Form S-4 ... New Notes was filed with the Securities and Exchange ...
(Date:3/26/2015)... , March 26, 2015 IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA) of ... submissions now pending at the FDA to twenty-three. ... the Company, commented, "On March 2, 2015, we committed ...
Breaking Medicine Technology:RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2
... Higher ... to Standard Chemotherapy, SEATTLE, Nov. 11 Cell Therapeutics, ... the primary,efficacy endpoint of its phase III EXTEND (PIX301) trial ... based on a preliminary intent to treat efficacy analysis.,Patients randomized ...
... Pharmasset, Inc.,(Nasdaq: VRUS ), Roche (SWX: ROG) and ... first patients have been dosed in an innovative clinical,trial ... (HCV).,The trial (run in centers in Australia and New ... oral antiviral molecules in the absence,of interferon., The ...
Cached Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....
... Hema-G Stains for Geometric Data ... performance. Stains are quality control ... to ensure proper staining and ... most applications for a minimum ...
... suspension in methanol for faster, more ... histology smears. Our special manufacturing process ... cellular elements producing unequaled definition of ... unexcelled brilliance in the resulting smear. ...
... For fast, single-solution staining, Hema-Quik ... Dip slides into stain solution ... transfer to deionized water for ... a second time by dipping ...
Medicine Products: